Also known as a polymyxin B haemoperfusion (PMX), Toraymyxin is a haemoperfusion device that removes endotoxin, a toxic ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

Radella Pharmaceuticals has reported topline outcomes from a Phase Ia trial that assessed an investigational therapy for ...

Lord Vallance stated the government sees investment, innovation, and public-private partnership as crucial to UK healthcare.

Treatments targeting alpha-synuclein aggregation account for 26% of the 7MM' pipeline disease-modifying therapies for ...

Minghui Pharmaceutical has reported promising initial outcomes from its Phase I trial of MHB039A to treat patients with solid ...

Ionis has announced the design for a Phase III trial of ION582, a treatment for Angelman syndrome (AS), following discussions with the FDA.

Alcon’s session at the 2024 Veeva MedTech Summit in Amsterdam. Image Credit: Ross Law / GlobalData. Alcon decided to take a ...

Castle’s DecisionDx-Melanoma test is one of the company’s most in-demand products. Image credit: Pressmaster / Shutterstock. Castle Biosciences has released data from a multi-centre DECIDE study ...

The former health minister predicted a bright future for UK trials and outlined steps to ensure clinical research thrives.

Penumbra has developed a microprocessor with thrombus removal algorithms that, combined with audio-visual feedback, help ...

Zymeworks has dosed the first patient in its Phase I clinical trial of ZW191 aimed at treating advanced solid tumours.